Latest Clinical Trials
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer H. Lee Moffitt Cancer Center and Research Institute NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer University of California, San Francisco NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial Alliance for Clinical Trials in Oncology NA
RECRUITING
(Sep 1, 2026)
PHASE3 Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer Institute of Cancer Research, United Kingdom NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) University of Arkansas NA
RECRUITING
(Sep 1, 2026)
PHASE2 Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer University College, London NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs Kokilaben Dheerubhai Ambani Hospital and Research NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial NRG Oncology NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma Janssen Pharmaceutical K.K. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial NRG Oncology NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Janssen Pharmaceutica N.V., Belgium NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 The Effect of Metformin in Patients With Newly Diagnosed mHSPC Sun Yat-sen University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) Alliance for Clinical Trials in Oncology NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer Janssen Research & Development, LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1 Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer Sun Yat-sen University NA
RECRUITING
(Aug 1, 2026)
PHASE2 Study of Oral MRT-2359 With Apalutamide in Prostate Cancer Monte Rosa Therapeutics, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer Astellas Pharma Global Development, Inc. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Rahul Aggarwal NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study of ORIC-944 in Patients With Metastatic Prostate Cancer ORIC Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE1 Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial Jonsson Comprehensive Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE3 Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Mayo Clinic NA
RECRUITING
(Jul 1, 2026)
PHASE2 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging ECOG-ACRIN Cancer Research Group NA
RECRUITING
(Jun 1, 2026)
PHASE3 The COSMYC Trial (COmbined Suppression of MYC) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
RECRUITING
(Jun 1, 2026)
PHASE2 Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD NA
RECRUITING
(Jun 1, 2026)
PHASE3 RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Georgetown University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy University of Wisconsin, Madison NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland National Cancer Institute (NCI) NA
COMPLETED
(May 1, 2026)
PHASE2 Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection Blue Earth Therapeutics Ltd NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy Prostate Cancer Clinical Trials Consortium NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial NRG Oncology NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Sir Mortimer B. Davis - Jewish General Hospital NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases Janssen Research & Development, LLC NA
COMPLETED
(Apr 1, 2026)
PHASE2 Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer VA Office of Research and Development NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer Weill Medical College of Cornell University NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer University of Wisconsin, Madison NA
RECRUITING
(Apr 1, 2026)
PHASE1 Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study University of Washington NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer Institut Paoli-Calmettes NA
COMPLETED
(Mar 1, 2026)
PHASE2 Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer The Methodist Hospital Research Institute NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 
